Difficulty: Medium
Average Score: 81%
Practice
The substance binding to one receptor subtype as an agonist and to another as an antagonist is called:
Correct answer
C
Rationale
In pharmacology, understanding the concept of substances that can act as both agonists and antagonists on different receptor subtypes is crucial for effective medication management across the lifespan. The correct answer is C) Agonist-antagonist.
An agonist-antagonist is a substance that binds to one type of receptor as an agonist, activating it to produce a response, and binds to another type of receptor as an antagonist, blocking its activity. This dual action can be beneficial in certain clinical scenarios where a balanced effect is needed, such as managing pain with opioid medications like buprenorphine.
Now, let's analyze why the other options are incorrect:
- A) Competitive antagonist: This type of antagonist competes with the agonist for binding to the same receptor site, but it does not exhibit dual agonist-antagonist activity on different receptor subtypes.
- B) Irreversible antagonist: Irreversible antagonists bind permanently to receptors, rendering them inactive. They do not have the dual functionality of an agonist-antagonist.
- D) Partial agonist: A partial agonist activates a receptor but to a lesser extent than a full agonist. While it has agonistic activity, it does not exhibit antagonist activity on another receptor subtype simultaneously.
Understanding these distinctions is vital for healthcare professionals to make informed decisions when selecting medications for patients of different age groups. It highlights the complexities of pharmacological interactions and the importance of tailoring treatment approaches based on individual patient needs across the lifespan.
An agonist-antagonist is a substance that binds to one type of receptor as an agonist, activating it to produce a response, and binds to another type of receptor as an antagonist, blocking its activity. This dual action can be beneficial in certain clinical scenarios where a balanced effect is needed, such as managing pain with opioid medications like buprenorphine.
Now, let's analyze why the other options are incorrect:
- A) Competitive antagonist: This type of antagonist competes with the agonist for binding to the same receptor site, but it does not exhibit dual agonist-antagonist activity on different receptor subtypes.
- B) Irreversible antagonist: Irreversible antagonists bind permanently to receptors, rendering them inactive. They do not have the dual functionality of an agonist-antagonist.
- D) Partial agonist: A partial agonist activates a receptor but to a lesser extent than a full agonist. While it has agonistic activity, it does not exhibit antagonist activity on another receptor subtype simultaneously.
Understanding these distinctions is vital for healthcare professionals to make informed decisions when selecting medications for patients of different age groups. It highlights the complexities of pharmacological interactions and the importance of tailoring treatment approaches based on individual patient needs across the lifespan.